A biomarker study for evaluating MN-166 in methamphetamine use disorder
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
Price : $35 *
At a glance
- Drugs Ibudilast (Primary)
- Indications Substance-related disorders
- Focus Biomarker; Pharmacodynamics
- 16 Nov 2017 New trial record
- 09 Nov 2017 According to a MediciNova media release, this study has already completed FDA review and will be initiated by Dr. William Hoffman at Portland VA Medical Center and Oregon Health & Science University.
- 09 Nov 2017 According to a MediciNova media release, this study is supported by the U.S. Department of Veterans Affairs.